Synairgen shares rise after announcing 'excellent progress' in separate studies 1 234 567

Synairgen shares rise after announcing 'excellent progress' in separate studies

livecharts.co.uk

Synairgen announced on Wednesday it had narrowed its operating loss for the six months leading to 30 June thanks to "excellent progress" made in the development of its Lysyl Oxidase-Like 2 (LOXL2) enzyme inhibitor, and its AZD9412 (SNG001) programme.

Full news

Share:

More:

1 234 567

1 234 567

1 234 567

1 234 567

1 234 567

1 234 567